Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Atherosclerosis Reports
Erschienen in: Current Atherosclerosis Reports 6/2012

01.12.2012 | Nutrition (BV Howard, Section Editor)

Arsenic Exposure and Cardiovascular Disease:An Updated Systematic Review

verfasst von: Katherine Moon, Eliseo Guallar, Ana Navas-Acien

Erschienen in: Current Atherosclerosis Reports | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

In epidemiologic studies, high-chronic arsenic exposure has been associated with cardiovascular disease, despite methodological limitations. At low-moderate arsenic levels, the evidence was inconclusive. Here, we update a previous systematic review (Am J Epidemiol 2005;162:1037–49) examining the association between arsenic exposure and cardiovascular disease. Eighteen studies published since 2005 were combined with 13 studies from the previous review. We calculated pooled relative risks by comparing the highest versus the lowest exposure category across studies. For high exposure (arsenic in drinking water > 50 μg/L), the pooled relative risks (95 % confidence interval) for cardiovascular disease, coronary heart disease, stroke, and peripheral arterial disease were 1.32 (95 % CI:1.05–1.67), 1.89 (95 % CI:1.33–2.69), 1.08 (95 % CI:0.98–1.19), and 2.17 (95 % CI:1.47–3.20), respectively. At low-moderate arsenic levels, the evidence was inconclusive. Our review strengthens the evidence for a causal association between high-chronic arsenic exposure and clinical cardiovascular endpoints. Additional high quality studies are needed at low-moderate arsenic levels.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
National Research Council. Arsenic in drinking water. Washington, DC: National Academy Press; 1999.
2.
EFSA (European Food Safety Authority). Panel on contaminants in the food chain. Scientific opinion on arsenic in food. EFSA J. 2009;7(10):1351.
3.
4.
5.
6.
Navas-Acien A, Sharrett AR, Silbergeld EK, Schwartz BS, Nachman KE, Burke TA, et al. Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol. 2005;162(11):1037–49.PubMedCrossRef
7.
Wang C-H, Hsiao CK, Chen C-L, Hsu L-I, Chiou H-Y, Chen S-Y, et al. A review of the epidemiologic literature on the role of environmental arsenic exposure and cardiovascular diseases. Toxicol Appl Pharmacol. 2007;222(3):315–26.PubMedCrossRef
8.
Tseng C-H. Blackfoot disease and arsenic: a never-ending story. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2005;23(1):55–74.PubMedCrossRef
9.
Tseng C-H. Cardiovascular disease in arsenic-exposed subjects living in the arseniasis-hyperendemic areas in Taiwan. Atherosclerosis. 2008;199(1):12–8.PubMedCrossRef
10.
Alissa EM, Ferns GA. Heavy metal poisoning and cardiovascular disease. J Toxicol. 2011;2011:870125.PubMed
11.
Balakumar P, Kaur J. Arsenic exposure and cardiovascular disorders: an overview. Cardiovasc Toxicol. 2009;9(4):169–76.PubMedCrossRef
12.
Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology. 2011;283(2–3):65–87.PubMedCrossRef
13.
Cheng T-J, Chuu J-J, Chang C-Y, Tsai W-C, Chen K-J, Guo H-R. Atherosclerosis induced by arsenic in drinking water in rats through altering lipid metabolism. Toxicol Appl Pharmacol. 2011;256(2):146–53.PubMedCrossRef
14.
Tsou T-C, Yeh SC, Tsai E-M, Tsai F-Y, Chao H-R, Chang LW. Arsenite enhances tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1. Toxicol Appl Pharmacol. 2005;209(1):10–8.PubMedCrossRef
15.
Chen S-C, Tsai M-H, Wang H-J, Yu H-S, Chang LW. Involvement of substance P and neurogenic inflammation in arsenic-induced early vascular dysfunction. Toxicol Sci. 2007;95(1):82–8.PubMedCrossRef
16.
States JC, Srivastava S, Chen Y, Barchowsky A. Arsenic and cardiovascular disease. Toxicol Sci. 2009;107(2):312–23.PubMedCrossRef
17.
States JC, Barchowsky A, Cartwright IL, Reichard JF, Futscher BW, Lantz RC. Arsenic toxicology: translating between experimental models and human pathology. Environ Health Perspect. 2011;119(10):1356–63.PubMedCrossRef
18.
Chiu H-F, Lin M-C, Yang C-Y. Primary intracerebral hemorrhage mortality reduction after installation of a tap-water supply system in an arseniasis-endemic area in southwestern Taiwan. J Toxicol Environ Health Part A. 2007;70(6):539–46.PubMedCrossRef
19.
Yang C-Y. Does arsenic exposure increase the risk of development of peripheral vascular diseases in humans? J Toxicol Environ Health Part A. 2006;69(19):1797–804.PubMedCrossRef
20.
Franklin M, Koutrakis P, Schwartz P. The role of particle composition on the association between PM2.5 and mortality. Epidemiology. 2008;19(5):680–9.PubMedCrossRef
21.
Tsai J-L, Horng P-H, Hwang T-J, Hsu JW, Horng C-J. Determination of urinary trace elements (arsenic, copper, cadmium, manganese, lead, zinc, selenium) in patients with Blackfoot disease. Arch Environ Health. 2004;59(12):686–92.PubMedCrossRef
22.
Wang C-H, Chen C-L, Hsiao CK, Chiang F-T, Hsu L-I, Chiou H-Y, et al. Arsenic-induced QT dispersion is associated with atherosclerotic diseases and predicts long-term cardiovascular mortality in subjects with previous exposure to arsenic: A 17-Year follow-up study. Cardiovasc Toxicol. 2010;10(1):17–26.PubMedCrossRef
23.
Tseng C-H, Chong C-K, Tseng C-P, Hsueh Y-M, Chiou H-Y, Tseng C-C, et al. Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan. Toxicol Lett. 2003;137(1–2):15–21.PubMedCrossRef
24.
Tseng C-H, Huang Y-K, Huang Y-L, Chung C-J, Yang M-H, Chen C-J, et al. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol Appl Pharmacol. 2005;206(3):299–308.PubMedCrossRef
25.
Tseng CH, Chong CK, Chen CJ, Tai TY. Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Atherosclerosis. 1996;120(1–2):125–33.PubMedCrossRef
26.
Longnecker MP, Berlin JA, Orza MJ, Chalmers TC. A meta-analysis of alcohol consumption in relation to risk of breast cancer. JAMA. 1988;260(5):652–6.PubMedCrossRef
27.
Liao Y-T, Chen C-J, Li W-F, Hsu L-I, Tsai L-Y, Huang Y-L, et al. Elevated lactate dehydrogenase activity and increased cardiovascular mortality in the arsenic-endemic areas of southwestern Taiwan. Toxicology and applied pharmacology [Internet]. 2012 May 1; Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22569360
28.
•• Chen Y, Graziano JH, Parvez F, Liu M, Slavkovich V, Kalra T, et al. Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study. BMJ. 2011;342:d2431. In this large prospective cohort study in Bangladesh, exposure to arsenic was assessed using both individual drinking water and urine total arsenic levels. Arsenic was associated with increased cardiovascular disease, coronary heart disease, and stroke mortality. A synergistic effect between cigarette smoking and arsenic exposure on heart disease mortality was found. PubMedCrossRef
29.
• Sohel N, Persson LA, Rahman M, Streatfield PK, Yunus M, Ekström E-C, et al. Arsenic in drinking water and adult mortality: a population-based cohort study in rural Bangladesh. Epidemiology. 2009;20(6):824–30. In this large prospective cohort study from rural Bangladesh, arsenic levels in household drinking water were associated with an increased risk of cardiovascular disease mortality. There was a clear dose-response relationship, with an increased risk of mortality from cardiovascular disease even at relatively low levels of arsenic exposure (10–49 μg/L). PubMedCrossRef
30.
Wade TJ, Xia Y, Wu K, Li Y, Ning Z, Le XC, et al. Increased mortality associated with well-water arsenic exposure in Inner Mongolia, China. Int J Environ Res Public Health. 2009;6(3):1107–23.PubMedCrossRef
31.
• Lisabeth LD, Ahn HJ, Chen JJ, Sealy-Jefferson S, Burke JF, Meliker JR. Arsenic in drinking water and stroke hospitalizations in Michigan. Stroke. 2010;41(11):2499–504. An ecological study of 83 counties in Michigan, U.S., including a sub-analysis of 27 zip codes in Genesee County. Using population-weighted average levels of arsenic in drinking water, this study found a significant increased risk of ischemic stroke hospitalizations in Genesee county, comparing zip codes with average levels of arsenic of 22.3 μg/L versus 4.5 μg/L. PubMedCrossRef
32.
• Medrano MAJ, Boix R, Pastor-Barriuso R, Palau M, Damián J, Ramis R, et al. Arsenic in public water supplies and cardiovascular mortality in Spain. Environ Res. 2010;110(5):448–54. This ecological study from Spain used municipal drinking water levels of arsenic and found an increased risk of cardiovascular, coronary heart disease, and stroke mortality in municipalities with average levels of arsenic of 1–10 μg/L and <10 μg/L, compared to < 10 μg/L. The authors were able to adjust for many cardiovascular disease risk factors at the municipal or provincial level. PubMedCrossRef
33.
Wu M-M, Chiou H-Y, Chen C-L, Wang Y-H, Hsieh Y-C, Lien L-M, et al. GT-repeat polymorphism in the heme oxygenase-1 gene promoter is associated with cardiovascular mortality risk in an arsenic-exposed population in northeastern Taiwan. Toxicol Appl Pharmacol. 2010;248(3):226–33.PubMedCrossRef
34.
Cheng T-J, Ke D-S, Guo H-R. The association between arsenic exposure from drinking water and cerebrovascular disease mortality in Taiwan. Water Res. 2010;44(19):5770–6.PubMedCrossRef
35.
Horng C-J, Lin S-R. Determination of urinary trace elements (As, Hg, Zn, Pb, Se) in patients with Blackfoot disease. Talanta. 1997;45(1):75–83.PubMedCrossRef
36.
Khan MH, Sarkar S, Khan N, Sarwar AFM, Ahmad SA. Assessment of low ABSPI among arsenic exposed and non-exposed populations: a pilot study. Bangladesh Med Res Counc Bull. 2010;36(1):23–6.PubMedCrossRef
37.
Yuan Y, Marshall G, Ferreccio C, Steinmaus C, Selvin S, Liaw J, et al. Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed region II of Chile from 1950 to 2000. Am J Epidemiol. 2007;166(12):1381–91.PubMedCrossRef
38.
Xia Y, Wade TJ, Wu K, Li Y, Ning Z, Le XC, et al. Well water arsenic exposure, arsenic induced skin-lesions and self-reported morbidity in Inner Mongolia. Int J Environ Res Public Health. 2009;6(3):1010–25.PubMedCrossRef
39.
Afridi HI, Kazi TG, Kazi N, Kandhro GA, Baig JA, Shah AQ, et al. Evaluation of toxic elements in scalp hair samples of myocardial infarction patients at different stages as related to controls. Biol Trace Elem Res. 2010;134(1):1–12.PubMedCrossRef
40.
Afridi HI, Kazi TG, Kazi N, Kandhro GA, Baig JA, Jamali MK, et al. Association of environmental toxic elements in biological samples of myocardial infarction patients at different stages. Biol Trace Elem Res. 2011;141(1–3):26–40.PubMedCrossRef
41.
Gong G, O’Bryant SE. Low-level arsenic exposure, AS3MT gene polymorphism and cardiovascular diseases in rural Texas counties. Environ Res. 2012;113:52–7.PubMedCrossRef
42.
Rapant S, Cvecková V, Dietzová Z, Khun M, Letkovicová M. Medical geochemistry research in Spissko-Gemerské rudohorie Mts., Slovakia. Environ Geochem Health. 2009;31(1):11–25.PubMedCrossRef
43.
Yoshikawa M, Aoki K, Ebine N, Kusunoki M, Okamoto A. Correlation between the arsenic concentrations in the air and the SMR of lung cancer. Environ Health Prev Med. 2008;13(4):207–18.PubMedCrossRef
44.
Meliker JR, Wahl RL, Cameron LL, Nriagu JO. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ Health. 2007;6:4.PubMedCrossRef
45.
Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1–30.PubMed
46.
Harris RJ, Bradburn MJ, Deeks JJ, Harbord RM, Altman DG, Sterne JAC. Metan: fixed- and random-effects meta-analysis. Stata J. 2008;8(1):3–28.
47.
Deeks JJ, Altman DG, Bradburn MJ. Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis. Systematic Reviews in Health Care [Internet]. BMJ Publishing Group; 2001. p. 285–312. Available from: http://​dx.​doi.​org/​10.​1002/​9780470693926.​ch15
48.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.PubMedCrossRef
49.
Varsányi I, Fodré Z, Bartha A. Arsenic in drinking water and mortality in the Southern Great Plain, Hungary. Environ Geochem Heal. 1991;13(1):14–22.CrossRef
50.
StataCorp. Stata statistical software: release 12. College Station: StataCorp, LP; 2011.
51.
52.
Wang CT, Chang WT. Arterial tissue of arsenic, selenium and iron in Blackfoot disease patients. Clin Chem Lab Med. 2001;39(7):645–8.PubMedCrossRef
53.
Tsai SM, Wang TN, Ko YC. Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch Environ Health. 1999;54(3):186–93.PubMedCrossRef
54.
Lin SM, Yang MH. Arsenic, selenium, and zinc in patients with Blackfoot disease. Biol Trace Elem Res. 1988;15:213–21.PubMedCrossRef
55.
Chen CJ, Wu MM, Lee SS, Wang JD, Cheng SH, Wu HY. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis. 1988;8(5):452–60.PubMedCrossRef
56.
Chen CJ, Chiou HY, Chiang MH, Lin LJ, Tai TY. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol. 1996;16(4):504–10.PubMedCrossRef
57.
Chiou HY, Huang WI, Su CL, Chang SF, Hsu YH, Chen CJ. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke. 1997;28(9):1717–23.PubMedCrossRef
58.
Wu MM, Kuo TL, Hwang YH, Chen CJ. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol. 1989;130(6):1123–32.PubMed
59.
Zierold KM, Knobeloch L, Anderson H. Prevalence of chronic diseases in adults exposed to arsenic-contaminated drinking water. Am J Public Health. 2004;94(11):1936–7.PubMedCrossRef
60.
Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon RL. Drinking water arsenic in Utah: a cohort mortality study. Environ Health Perspect. 1999;107(5):359–65.PubMedCrossRef
61.
Ruiz-Navarro ML, Navarro-Alarcón M, De la Serrana Lopez González H, Pérez-Valero V, López-Martinez MC. Urine arsenic concentrations in healthy adults as indicators of environmental contamination: relation with some pathologies. Sci Total Environ. 1998;216(1-2):55–61.PubMedCrossRef
62.
Engel RR, Smith AH. Arsenic in drinking water and mortality from vascular disease: an ecologic analysis in 30 counties in the United States. Arch Environ Health. 1994;49(5):418–27.PubMedCrossRef
63.
Smith AH, Lingas EO, Rahman M. Contamination of drinking-water by arsenic in Bangladesh: a public health emergency. Bull World Health Organ. 2000;78(9):1093–103.PubMed
64.
Soto-Martinez M, Sly PD. Relationship between environmental exposures in children and adult lung disease: the case for outdoor exposures. Chron Respir Dis. 2010;7(3):173–86.PubMedCrossRef
65.
Smith AH, Steinmaus CM. Health effects of arsenic and chromium in drinking water: recent human findings. Annu Rev Public Health. 2009;30:107–22.PubMedCrossRef
66.
Abhyankar LN, Jones MR, Guallar E, Navas-Acien A. Arsenic exposure and hypertension: a systematic review. Environ Heal Perspect. 2011;120(4):494–500.CrossRef
67.
Navas-Acien A, Silbergeld EK, Streeter RA, Clark JM, Burke TA, Guallar E. Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect. 2006;114(5):641–8.PubMedCrossRef
68.
IPCS (International Programme on Chemical Safety). Environmental health criteria document 224: arsenic and arsenic compounds (second edition). Geneva: World Health Organization; 2001.
69.
Jackson BP, Taylor VF, Karagas MR, Punshon T, Cottingham KL. Arsenic, organic foods, and brown rice syrup. Environ Health Perspect. 2012;120(5):623–6.PubMedCrossRef
70.
Gilbert-Diamond D, Cottingham KL, Gruber JF, Punshon T, Sayarath V, Gandolfi AJ, et al. Rice consumption contributes to arsenic exposure in US women. Proc Natl Acad Sci U S A. 2011;108(51):20656–60.PubMedCrossRef
71.
Binks K, Doll R, Gillies M, Holroyd C, Jones SR, McGeoghegan D, et al. Mortality experience of male workers at a UK tin smelter. Occup Med (Lond). 2005;55(3):215–26.CrossRef
72.
Chen W, Yang J, Chen J, Bruch J. Exposures to silica mixed dust and cohort mortality study in tin mines: exposure-response analysis and risk assessment of lung cancer. Am J Ind Med. 2006;49(2):67–76.PubMedCrossRef
73.
Marsh GM, Esmen NA, Buchanich JM, Youk AO. Mortality patterns among workers exposed to arsenic, cadmium, and other substances in a copper smelter. Am J Ind Med. 2009;52(8):633–44.PubMedCrossRef
74.
Wang C-H, Jeng J-S, Yip P-K, Chen C-L, Hsu L-I, Hsueh Y-M, et al. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation. 2002;105(15):1804–9.PubMedCrossRef
75.
Chen Y, Hakim ME, Parvez F, Islam T, Rahman AM, Ahsan H. Arsenic exposure from drinking-water and carotid artery intima-medial thickness in healthy young adults in Bangladesh. J Health Popul Nutr. 2006;24(2):253–7.PubMed
76.
Navas-Acien A, Silbergeld EK, Pastor-Barriuso R, Guallar E. Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA. 2008;300(7):814–22.PubMedCrossRef
77.
Chen Y, Santella RM, Kibriya MG, Wang Q, Kappil M, Verret WJ, et al. Association between arsenic exposure from drinking water and plasma levels of soluble cell adhesion molecules. Environ Health Perspect. 2007;10:1415–20.
78.
Wu F, Jasmine F, Kibriya MG, Liu M, Wójcik O, Parvez F, et al. Association between arsenic exposure from drinking water and plasma levels of cardiovascular markers. Am J Epidemiol. 2012;175(12):1252–61.PubMedCrossRef
79.
Mordukhovich I, Wright RO, Amarasiriwardena C, Baja E, Baccarelli A, Suh H, et al. Association between low-level environmental arsenic exposure and QT interval duration in a general population study. Am J Epidemiol. 2009;170(6):739–46.PubMedCrossRef
80.
Mumford JL, Wu K, Xia Y, Kwok R, Yang Z, Foster J, et al. Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study. Environ Health Perspect. 2007;115(5):690–4.PubMedCrossRef
81.
Zhang Y, Post WS, Dalal D, Blasco-Colmenares E, Tomaselli GF, Guallar E. QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2011;171(19):1727–33.PubMedCrossRef
82.
Ahmad SA, Khatun F, Sayed MHSU, Khan MH, Aziz R, Hossain MZ, et al. Electrocardiographic abnormalities among arsenic-exposed persons through groundwater in Bangladesh. J Health Popul Nutr. 2006;24(2):221–7.PubMed
83.
Liao Y-T, Li W-F, Chen C-J, Prineas RJ, Chen WJ, Zhang Z-M, et al. Synergistic effect of polymorphisms of paraoxonase gene cluster and arsenic exposure on electrocardiogram abnormality. Toxicol Appl Pharmacol. 2009;239(2):178–83.PubMedCrossRef
84.
Wang C-H, Chen C-L, Hsiao CK, Chiang F-T, Hsu L-I, Chiou H-Y, et al. Increased risk of QT prolongation associated with atherosclerotic diseases in arseniasis-endemic area in southwestern coast of Taiwan. Toxicol Appl Pharmacol. 2009;239(3):320–4.PubMedCrossRef
85.
Wu M-M, Chiou H-Y, Hsueh Y-M, Hong C-T, Su C-L, Chang S-F, et al. Effect of plasma homocysteine level and urinary monomethylarsonic acid on the risk of arsenic-associated carotid atherosclerosis. Toxicol Appl Pharmacol. 2006;216(1):168–75.PubMedCrossRef
86.
Huang Y-L, Hsueh Y-M, Huang Y-K, Yip P-K, Yang M-H, Chen C-J. Urinary arsenic methylation capability and carotid atherosclerosis risk in subjects living in arsenicosis-hyperendemic areas in southwestern Taiwan. Sci Total Environ. 2009;407(8):2608–14.PubMedCrossRef
87.
Hsieh Y-C, Hsieh F-I, Lien L-M, Chou Y-L, Chiou H-Y, Chen C-J. Risk of carotid atherosclerosis associated with genetic polymorphisms of apolipoprotein E and inflammatory genes among arsenic exposed residents in Taiwan. Toxicol Appl Pharmacol. 2008;227(1):1–7.PubMedCrossRef
88.
Li W-F, Sun C-W, Cheng T-J, Chang K-H, Chen C-J, Wang S-L. Risk of carotid atherosclerosis is associated with low serum paraoxonase (PON1) activity among arsenic exposed residents in Southwestern Taiwan. Toxicol Appl Pharmacol. 2009;236(2):246–53.PubMedCrossRef
89.
Hsieh Y-C, Lien L-M, Chung W-T, Hsieh F-I, Hsieh P-F, Wu M-M, et al. Significantly increased risk of carotid atherosclerosis with arsenic exposure and polymorphisms in arsenic metabolism genes. Environ Res. 2011;111(6):804–10.PubMedCrossRef
90.
Vahter M, Akesson A, Lidén C, Ceccatelli S, Berglund M. Gender differences in the disposition and toxicity of metals. Environ Res. 2007;104(1):85–95.PubMedCrossRef
91.
Ren X, McHale CM, Skibola CF, Smith AH, Smith MT, Zhang L. An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. Environ Health Perspect. 2011;119(1):11–9.PubMedCrossRef
92.
Smeester L, Rager JE, Bailey KA, Guan X, Smith N, García-Vargas G, et al. Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol. 2011;24(2):165–7.PubMedCrossRef
Metadaten
Titel
Arsenic Exposure and Cardiovascular Disease:An Updated Systematic Review
verfasst von
Katherine Moon
Eliseo Guallar
Ana Navas-Acien
Publikationsdatum
01.12.2012
Verlag
Current Science Inc.
Erschienen in
Current Atherosclerosis Reports / Ausgabe 6/2012
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-012-0280-x

Weitere Artikel der Ausgabe 6/2012

Current Atherosclerosis Reports 6/2012 Zur Ausgabe

Lipid and Metabolic Effects of Gastrointestinal Surgery (F Rubino, Section Editor)

Bariatric/Metabolic Surgery: Short- and Long-Term Safety

Nutrition (1 BV Howard, Section Editor)

Fructose and Risk of Cardiometabolic Disease

Nutrition (BV Howard, Section Editor)

Alcohol Intake Revisited: Risks and Benefits

Lipid and Metabolic Effects of Gastrointestinal Surgery (F Rubino, Section Editor)

The Effect of Gastrointestinal Surgery on Insulin Resistance and Insulin Secretion

Lipid and Metabolic Effects of Gastrointestinal Surgery (F Rubino, Section Editor)

Mechanisms of Weight Loss, Diabetes Control and Changes in Food Choices After Gastrointestinal Surgery

Nutrition (BV Howard, Section Editor)

Recent Findings on the Effects of Marine-Derived n-3 Polyunsaturated Fatty Acids on Urinary Albumin Excretion and Renal Function

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise